Nal von minden GmbH

Business Strategies

nal von minden GmbH is a successful Biotechnology Company in the field of point-of-care-testing und laboratory diagnostics. We offer a comprehensive product portfolio of point-of-care tests, especially rapid tests, Elisa and Enzymatic Immuno Assays to customers all over the world. Our strong team of more then 100 employees comes from 10 different nations.

Our indications are drug analytic’s, infectiology, cardiology, gynaecology, paediatric, oncology, urine chemistry and bacteriology. nal von minden has the possibility to develop new antibody based rapid tests and is strongly interested in co-operations for the development of new products. Our customers are hospitals, clinics, doctors, labs, prisons, police and health authorities in nearly all European countries and worldwide.

Core Technologies

Our products are based on:

• Competitive Immuno Assays (Rapid Tests), e.g. drugs, hcg, FOB
• Drug of Abuse Elisa, e.g. Amphetamine Elisa, Buprenorphine Elisa
• Serological Elisa, e.g.EBV, EBNA
• Drug of Abuse - Enzymatic Immuno Assay technology (comparable to Syva Tests), e.g. EtG- and Buprenorphine EIA

Co-operations

nal von minden GmbH co-operation partners:

• Alere GmbH, Germany, Switzerland
• Immunalysis, USA

Distribution

nal von minden GmbH has established a direct sales organization for:
Austria, Belgium/Luxembourg, Finland, France, Germany, Ireland, Italy, Netherlands, Poland, Portugal, Romania, Sweden, Switzerland, Spain, United Kingdom.
We have more than 4000 customers in over 40 countries world wide.